Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000214989

Medchemexpress LLC 5-(4-butoxy-3-chlorophenyl)-N-((2-morpholinopyridin-3-yl)methyl)nicotinamide | 1266212-81-0 | >97.0% | 480.99 g/mol | C26H29ClN4O3 | 10 MG
SDP

Supplier:  Medchemexpress LLC HY10008010MG

Encompass_Preferred

A-887826 is a small-molecule, voltage-dependent NaV1.8 sodium channel blocker originally described by Abbott Laboratories. It is orally bioavailable, exhibits potent in vitro inhibition of NaV1.8 (IC50 ≈ 11 nM), and reduces neuropathic tactile allodynia in rodent models.

  • Potent NaV1.8 inhibition (IC50 ≈ 11 nM).
  • Orally bioavailable with demonstrated in vivo efficacy in neuropathic pain models.
  • Voltage-dependent block of tetrodotoxin-resistant (TTX-R) sodium currents.
  • Preferential selectivity versus NaV1.2 and NaV1.5 channels.
  • High purity suitable for research applications (≥97% HPLC).

Catalog No. 50-002-14989


May include imposed supplier surcharges.
Add to Cart

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.